文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

氧化三甲胺作为慢性肾脏病的潜在生物标志物和治疗靶点：综述

TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review.

作者信息

Zixin Ye, Lulu Chen, Xiangchang Zeng, Qing Fang, Binjie Zheng, Chunyang Luo, Tai Rao, Dongsheng Ouyang

机构信息

Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.

Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China.

出版信息

Front Pharmacol. 2022 Aug 12;13:929262. doi: 10.3389/fphar.2022.929262. eCollection 2022.

DOI:10.3389/fphar.2022.929262
PMID:36034781
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9411716/
Abstract

The gut microbiota and its metabolites have become a hotspot of recent research. Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to many diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes, etc. Chronic kidney disease (CKD) is an important contributor to morbidity and mortality from non-communicable diseases. Recently, increasing focus has been put on the role of TMAO in the development and progress of chronic kidney disease. The level of TMAO in patients with chronic kidney disease is significantly increased, and a high level of TMAO deteriorates chronic kidney disease. This article describes the relationship between TMAO and chronic kidney disease and the research progress of drugs targeted TMAO, providing a reference for the development of anti-chronic kidney disease drugs targeted TMAO.

摘要

肠道微生物群及其代谢产物已成为近期研究的热点。由肠道微生物群代谢产生的氧化三甲胺（TMAO）与许多疾病密切相关，如心血管疾病、慢性肾脏病、2型糖尿病等。慢性肾脏病（CKD）是导致非传染性疾病发病和死亡的重要因素。近年来，人们越来越关注TMAO在慢性肾脏病发生发展中的作用。慢性肾脏病患者体内TMAO水平显著升高，而高水平的TMAO会使慢性肾脏病恶化。本文阐述了TMAO与慢性肾脏病的关系以及靶向TMAO的药物研究进展，为开发靶向TMAO的抗慢性肾脏病药物提供参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba80/9411716/9e78756b0bf0/fphar-13-929262-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba80/9411716/45ef9cd5870a/fphar-13-929262-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba80/9411716/9e78756b0bf0/fphar-13-929262-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba80/9411716/45ef9cd5870a/fphar-13-929262-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ba80/9411716/9e78756b0bf0/fphar-13-929262-g002.jpg

相似文献

[1]
TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review.

Front Pharmacol. 2022-8-12

[2]
Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease.

Circ Res. 2015-1-30

[3]
Gut microbiota-derived trimethylamine N-oxide is associated with the risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and dose-response meta-analysis.

Ann Med. 2023-12

[4]
From heart failure and kidney dysfunction to cardiorenal syndrome: TMAO may be a bridge.

Front Pharmacol. 2023-11-21

[5]
[Effect of traditional Chinese medicine in attenuating chronic kidney disease and its complications by regulating gut microbiota-derived metabolite trimethylamine N-oxide: a review].

Zhongguo Zhong Yao Za Zhi. 2023-1

[6]
Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease.

Arterioscler Thromb Vasc Biol. 2020-3-26

[7]
Exploring the Microbiome in Heart Failure.

Curr Heart Fail Rep. 2016-4

[8]
Trimethylamine N-Oxide as a Potential Biomarker for Cardiovascular Disease: Its Association with Dietary Sources of Trimethylamine N-Oxide and Microbiota.

Eurasian J Med. 2023-10

[9]
Trimethylamine N-Oxide as a Potential Risk Factor for Non-communicable Diseases: A Systematic Review.

Endocr Metab Immune Disord Drug Targets. 2023

[10]
Gut Microbiota-Dependent Trimethylamine-N-oxide and Serum Biomarkers in Patients with T2DM and Advanced CKD.

J Clin Med. 2017-9-19

引用本文的文献

[1]
Advancements in the non-invasive diagnosis of renal fibrosis.

Front Med (Lausanne). 2025-7-30

[2]
The role of trimethylamine N-oxide in disease pathogenesis and the therapeutic potential of traditional Chinese medicine.

Front Pharmacol. 2025-7-24

[3]
Gut Microbiome Diversity and Uric Acid in Serum and Urine.

Kidney Int Rep. 2025-4-3

[4]
Impact of gut microbiota in chronic kidney disease: natural polyphenols as beneficial regulators.

Ren Fail. 2025-12

[5]
Multiplatform Metabolomic Profiling of the Unilateral Ureteral Obstruction Murine Model of CKD.

Int J Mol Sci. 2025-5-21

[6]
Breastfeeding and Future Cardiovascular, Kidney, and Metabolic Health-A Narrative Review.

Nutrients. 2025-3-12

[7]
Characterising functional redundancy in microbiome communities via relative entropy.

Comput Struct Biotechnol J. 2025-3-12

[8]
The microbiome-derived metabolite trimethylamine N-oxide is associated with chronic kidney disease risk.

Appl Microbiol Biotechnol. 2025-4-22

[9]
The gut-heart axis: a review of gut microbiota, dysbiosis, and cardiovascular disease development.

Ann Med Surg (Lond). 2025-1-9

[10]
Animal Models for Studying Developmental Origins of Cardiovascular-Kidney-Metabolic Syndrome.

Biomedicines. 2025-2-12

本文引用的文献

[1]
Circulating Trimethylamine-N-Oxide and Risk of All-Cause and Cardiovascular Mortality in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Front Med (Lausanne). 2022-4-1

[2]
Metabolomics analysis of human plasma reveals decreased production of trimethylamine N-oxide retards the progression of chronic kidney disease.

Br J Pharmacol. 2022-9

[3]
A simplified LC-MS/MS method for the quantification of the cardiovascular disease biomarker trimethylamine--oxide and its precursors.

J Pharm Anal. 2021-8

[4]
High-fat diet-induced colonocyte dysfunction escalates microbiota-derived trimethylamine -oxide.

Science. 2021-8-13

[5]
Trimethylamine N-Oxide Exacerbates Renal Inflammation and Fibrosis in Rats With Diabetic Kidney Disease.

Front Physiol. 2021-6-16

[6]
Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome.

NPJ Biofilms Microbiomes. 2021-4-16

[7]
Use of dietary phytochemicals for inhibition of trimethylamine N-oxide formation.

J Nutr Biochem. 2021-5

[8]
Gut microbiota derived trimethylamine N-oxide (TMAO) detection through molecularly imprinted polymer based sensor.

Sci Rep. 2021-1-14

[9]
Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.

Sci Rep. 2021-1-12

[10]
Drug Discovery and Development of Novel Therapeutics for Inhibiting TMAO in Models of Atherosclerosis and Diabetes.

Front Physiol. 2020-10-29

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索